Table 2.
Univariate analysis of the association between the blood and laboratory variables and poor outcome of patients with coronavirus disease‐2019
|
All patients (n = 87) M = 49 (56.3%) F = 38 (43.7%) |
Non‐adverse prognosis group (n = 51) M = 27 (52.9%) F = 24 (47.1%) |
Adverse prognosis group (n = 36) M = 22 (61.1%) F = 14 (38.9%) |
P value | |
|---|---|---|---|---|
| White blood cell count (35‐95 G/L) | 5.49 (4.11‐7.02) | 5.05 (4.06‐6.48) | 5.72 (4.29‐8.26) | .049 |
| Increased | 10 (11.5%) | 2 (3.9%) | 8 (22.2%) | .041 |
| Decreased | 10 (11.5%) | 6 (11.8) | 4 (11.1%) | |
|
Neutrophil count (18‐63 G/L) |
3.3 (2.20‐4.09) | 3.32 (2.2‐4.09) | 5.08 (3.37‐7.64) | <.001 |
| Increased | 14 (16.1%) | 1 (2.0%) | 13 (36.1%) | |
|
Lymphocytes (11‐32 G/L) |
1.21 ± 0.60 | 1.44 ± 0.44) | 0.88 ± 0.65 | <.001 |
| Decreased | 36 (41.3%) | 12 (23.5%) | 24 (66.7%) | |
|
Monocyte count (0.1‐0.6 G/L) |
0.35 (0.25‐0.50) | 0.36 (0.34‐0.45) | 0.28 (0.15‐0.61) | .990 |
| Increased | 11 (13%) | 3 (5.8%) | 8 (22.2%) | |
| NLR | 2.87 (1.95‐5.73) | 2.2 (1.56‐2.87) | 6.78 (3.79‐11.85) | <.001 |
|
Platelet count (1250‐3500 G/L) |
207 (152‐259) | 203 (155‐236) | 219.5 (141.25‐312.75) | .727 |
|
Blood biochemistry glutamyl transpeptidase (100‐600 U/L) |
30.0 (22.0‐68.0) | 26 (21‐43) | 50 (24.5‐113.5) | .004 |
| Increased | 23 (26.4%) | 6 (11.7%) | 17 (47.2%) | |
|
LDH (1090‐2450 U/L) |
204 (164.0‐281.0) | 179 (156‐225) | 270 (189.5‐441.0) | <.001 |
| Increased | 31 (35.6%) | 9 (17.6%) | 22 (61.1%) | |
|
Albumin (330‐550 g/L) |
33.4 ± 6.1 | 36.2 ± 5.1 | 29.3 ± 5.1 | <.001 |
| Decreased | 39 (44.8%) | 11 (21.6%) | 28 (77.8%) | |
|
AGR (150%‐250%) |
1.10 ± 0.29 | 1.24 ± 0.23 | 0.91 ± 0.25 | <.001 |
| Decreased | 77 (88.5%) | 41 (80.4%) | 36 (100%) | |
|
Blood urea nitrogen (2.9‐8.2 mmol/L) |
4.78 (3.98‐6.60) | 4.56 (3.92‐5.42) | 5.33 (4.05‐7.42) | .05 |
|
Serum creatinine (570‐1110 μmol/L) |
67.9 (55.5‐78.2) | 67.3 (54.4‐80.8) | 68.8 (58.5‐77.7) | .549 |
| Increased | 3 (3.4%) | 0 | 3 (8.3%) | |
| Decreased | 24 (27.6%) | 16 (31.4%) | 8 (22.2%) | |
|
Glucose (3.9‐6.1 mmol/L) |
5.87 (5.27‐7.45) | 5.64 (5.10‐6.5) | 6.48 (5.36‐10.47) | .003 |
| Increased | 37 (42.5%) | 15 (29.4%) | 22 (61.1%) | |
|
Interleukin‐2 (0.10‐4.10 pg/mL) |
4.39 ± 0.61 | 4.32 ± 0.64 | 4.49 ± 0.55 | .209 |
|
Interleukin‐4 (0.10‐3.20 pg/mL) |
4.40 ± 1.22 | 4.23 ± 1.22 | 4.49 ± 0.53 | .104 |
| Increased | 83 (95.4%) | 41 (80.4%) | 32 (88.9%) | |
|
Interleukin‐6 (<7 pg/mL) |
7.0 (4.87‐11.2) | 5.20 (3.7‐7.0) | 10.0 (10.1‐29.0) | <.001 |
| Increased | 47 (54.0%) | 17 (33.3%) | 31 (86.1%) | |
|
Interleukin‐8 (0.10‐5.90 pg/mL) |
5.53 ± 1.32 | 5.34 ± 1.39 | 5.79 ± 1.26 | .131 |
| Increased | 22 (25.3%) | 13 (25.6%) | 9 (25.0%) | |
|
Tumor necrosis factor‐alpha (0.10‐23 pg/mL) |
4.05 (2.69‐5.16) | 3.68 (2.59‐5.16) | 4.08 (2.80‐4.90) | .315 |
|
Interferon‐γ (0.10‐18.00 pg/mL) |
3.98 (3.50‐4.66) | 3.98 (3.50‐4.62) | 3.98 (3.52‐4.92) | .353 |
The data are presented in median (range), n (%). Normally distributed measurement data were presented as Mean ± standard deviation (SD). Non‐normally distributed measurement data were presented in median (interquartile range [IQR]). SI conversion factors: To convert lactate dehydrogenase level to μkat/L, multiply by 0.0167. The P‐values that compared the adverse prognosis group and non‐adverse prognosis group were obtained from the chi‐square test, t test or Mann‐Whitney test.
Abbreviations: AGR, the albumin to globulin ratio; F, Female;G, ×109 cells; LDH, Lactate dehydrogenase; M, Male; NLR, The neutrophil‐to‐lymphocyte ratio; T: ×109 cells.